Zobrazeno 1 - 10
of 37
pro vyhledávání: ''
Autor:
Sudeep Banerjee, Robert J. Wechsler-Reya, Jill P. Mesirov, Alexander T. Wenzel, Hyunho Yoon, Huwate Yeerna, Chih-Min Tang, Mayra Yebra, Pablo Tamayo, Stephanie Ting, Jason K. Sicklick
Publikováno v:
Molecular Cancer Therapeutics. 20:2035-2048
Gastrointestinal stromal tumor (GIST) is commonly driven by oncogenic KIT mutations that are effectively targeted by imatinib (IM), a tyrosine kinase inhibitor (TKI). However, IM does not cure GIST, and adjuvant therapy only delays recurrence in high
Autor:
Alexander J. Lazar, Roman Groisberg, Vivek Subbiah, Robert E. Brown, Daniella E Portal, Aung Naing, Neeta Somaiah, Maria Alejandra Zarzour, Cynthia E. Herzog, Jason Roszik, Anthony P. Conley, David S. Hong, Shreyaskumar Patel
Publikováno v:
Mol Cancer Ther
Overexpression of transcription factor 3 in alveolar soft part sarcoma(ASPS) results in upregulation of cell proliferation pathways. No standard treatment algorithm exists for ASPS; multikinase inhibitors[tyrosine kinase inhibitor (TKI)] and immune c
Autor:
Tamika Mitchell, Irmina Diala, Vidyalakshmi Sethunath, Ragini Mistry, Rachel Schiff, Fabio Stossi, Sarmistha Nanda, Mothaffar F. Rimawi, Meenakshi Anurag, Martin Shea, Chia Chia Liu, Alshad S. Lalani, Michael A. Mancini, C. Kent Osborne, Sreyashree Bose, Jamunarani Veeraraghavan
Publikováno v:
Cancer Research. 81:1077-1077
The role of HER2 and PIK3CA mutations in anti-HER2 resistance is gaining more importance in HER2-positive (+) breast cancer. We recently reported that acquired resistance to lapatinib (Lap)-containing regimens is mediated by HER2 L755S, which could b
Autor:
Byung-Gyu Kim, Hye Jin Ham, Jung-Guk Kim, Ji-Hyun Kim, Soo-Young Park, Keun-Gyu Park, Jung Yi Lee, Yeon-Kyung Choi, Se Young Jang, Mi Jin Kim, Hui-Jeon Jeon, Inkyu Lee
Publikováno v:
Molecular Cancer Research. 15:1230-1242
The tyrosine kinase inhibitor sorafenib is the only therapeutic agent approved for the treatment of advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib is high. Here, we report metabolic reprogramming in sorafenib-resistant
Autor:
Imad Shureiqi
Publikováno v:
Cancer Prevention Research. 11:1-3
Patients with familial adenomatous polyposis (FAP) have an increased risk of developing duodenal adenomas and adenocarcinomas. In previous trials, sulindac (a cyclooxygenase inhibitor) alone failed to significantly suppress duodenal tumorigenesis in
Publikováno v:
Cancer Research. 80:1886-1886
Osimeritinib, a Tyrosine Kinase Inhibitor (TKI) has become a first-line therapy in EGFR-mutant NSCLC patients. Resistance to Osimeritinib treatment may occur due to acquired C797S mutations, MET amplifications and ALK rearrangements and other mechani
Autor:
Mothaffar F. Rimawi, Ragini Mistry, Fabio Stossi, Martin Shea, Jamunarani Veeraraghavan, C. Kent Osborne, Meenakshi Anurag, Vidyalakshmi Sethunath, Rachel Schiff, Michael A. Mancini, Sarmistha Nanda, Tamika Mitchell
Publikováno v:
Cancer Research. 80:1911-1911
Despite the availability of potent HER-targeted agents, de novo and acquired resistance is common and continues to pose a major challenge, especially in the advanced setting. Amassing evidence point to the importance of HER2 mutations, including the
Publikováno v:
Cancer Research. 80:4490-4490
Objective: Lung cancer is one of the leading causes of cancer-related mortality in the world, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. With the emergence of epidermal growth factor receptor tyrosine k
Publikováno v:
Cancer Immunology Research. 8:B57-B57
Objective: Non-small cell lung cancer (NSCLC) patients with specific EGFR mutations benefited from the emergence of EGFR tyrosine kinase inhibitors (EGFR-TKIs). Unfortunately, almost all cases eventually recrudesced after a median of 10 months. Thera
Autor:
Naoya Fujita, Elizabeth L. Lockerman, Yuka Kobayashi, Ryohei Katayama, Luc Friboulet, Alice T. Shaw, Sumie Koike, Jeffrey A. Engelman
Publikováno v:
Clinical Cancer Research. 21:166-174
Purpose: ROS1 rearrangement leads to constitutive ROS1 activation with potent transforming activity. In an ongoing phase I trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib shows remarkable initial responses in patients with non–small cell